Związki galu : szansa dla medycyny XXI wieku

• Autorzy: Miernicka M. , Budzisz E.

Warianty tytułu

EN

Gallium compounds - chance for medicine of XXI Century

• Języki publikacji: PL

Abstrakty

EN

Gallium(III) salts have been explored for their antineoplastic properties since 60. of XX century, but clinical experience has revealed unfavorable toxicological and pharmacokinetic properties. Much of the present knowledge about the biodistribution of gallium compounds stems from the application of gallium radionuclides in tumor diagnosis. Half and century ago, when the affinity of gallium for bone was recognized, the use of gallium(III) radionuclides for diagnosis and radiotherapy of osteogenic sarcoma was first proposed. However, interest in the broader potential of gallium in tumor therapy has only been stimulated by the discovery of the antineo-plastic properties of cisplatin and the observation of a tendency of gallium to accumulate in various tumors, soft tissues and sites of inflammation. The concept of an investigation of antineoplastic gallium(III) complexes are essentially derived from experience with gallium(III) nitrate and chloride. Attempts to improve the pharmacological effects by changing the way of administration were granted insufficient success to justify further investigation as cancer therapeutics. However, recent years have seen renewed interest in gallium compounds, because the oral application of gallium(III) complexes with organic ligands has been recognized as a way to overcome the limitations of gallium(III) nitrate and chloride. Two of these gallium(III) complexes - gallium maltolate and KP46 - have reached the clinical trials. Gallium(III) complexes based on other ligands are noticeably underexplored.

Słowa kluczowe

PL

sole galu(III); kompleksy galu(III); właściwości przeciwnowotworowe

EN

gallium(III) salts; gallium(III) complexes; antineoplastic properties

• Wydawca: Polskie Towarzystwo Chemiczne
• Czasopismo: Wiadomości Chemiczne
• Rocznik: 2007
• Tom: [Z] 61, 11-12
• Strony: 937--962
• Opis fizyczny: bibliogr. 156 poz., wykr.

Twórcy

autor

Miernicka M.

autor

Budzisz E.

• Zakład Chemii Surowców Kosmetycznych Wydział Farmaceutyczny Uniwersytetu Medycznego w Łodzi, ul. Muszyńskiego 1, 90-151 Łódź

Bibliografia

• [1] E. Matczak-Jon, Wiad. Chem., 1994, 48, 1, 3.
• [2] H.C. Dudley, G.W. Imirie Jr., J.T. Istock, Ragiology, 1950, 55, 571.
• [3] C.L. Edwards, R.L. Hayes, J. Nucl. Med., 1969, 10, 103.
• [4] C.L. Edwards, R.L. Hayes, J. Amer. Med. Ass., 1970, 212, 1182.
• [5] R.L. Hayes, Semin. Nucl. Med., 1978, 8, 183.
• [6] H. Van derWall, A.F. McLaughlin, A.E. Southee, [w:] Nuclear medicine in Clinical Diagnosis and Treatment (I.P.C. Murray, P.J. Ell, eds), vol. 2, 2nd ed., Churchill Livingston, 1998, pp. 813.
• [7] P.C. Huijgens, A.R. Jonkhoff, O.S. Hoekstra, G.J. Ossenkoppele, G.J.J. Teule, Eur. J. Haematol., 1993, 51, 206.
• [8] A.R. Jonkhoff, M.A.B.D. Plaizier, G.J. Ossenkoppele, G.J.J. Teule, P.C. Hiujgens, Br. J. Cancer, 1995, 72, 1541.
• [9] R.P. Warrel Jr., N.W. Alcock, R.S. Bockman, J. Clin. Oncol., 1987, 5, 29.
• [10] R.P. Warrel Jr., Cancer, 1997, 80 (suppl. 8), 1680.
• [11] M.M. Hart, R.H. Adamson, Proc. Natl. Acad. Sci. USA, 1971, 68, 1623.
• [12] M.M. Hart, C.F. Smith, S.T. Yancey, R.H. Adamson, J. Natl. Cancer Inst., 1971, 47, 1121.
• [13] R.H. Adamson, G.P. Canellos, S.M. Sieber, Cancer Chemother. Rep., 1975, 59, 599.
• [14] T. Pieper, K. Borsky, B.K. Keppler, Top. Biol. Inorg. Chem., 1999, 1, 171.
• [15] M.J. Clarke, F. Zhu, D.R. Frasca, Chem. Rev., 1999, 99, 2511.
• [16] R.P. Warrel Jr., C.J. Coonley, D.J. Straus, C.W. Young, Cancer, 1983, 51, 1982.
• [17] J.K. Weick, R.L. Stephens, L.H. Baker, S.E. Jones, Cancer Trat. Rep., 1983, 67, 823.
• [18] E.D. Crawford, J.H. Saiers, L.H. Baker, J.H. Constanzi, R.M. Bukowski, Urology, 1991, 38, 355.
• [19] P.A. Seligman, E.D. Crawford, J. Natl. Cancer Inst., 1991, 83, 1582.
• [20] A.D. Seidman, H.I. Scher, M.H. Heinemann, D.F. Bajorin, C.N. Sternberg, D.D. Dershaw, M. Silverberg, G.J. Bosl, Cancer, 1991, 68, 2561.
• [21] L.R. Bernstein, Pharmacol. Rev., 1998, 50, 6.
• [22] H.I. Scher, T. Curley, N. Geller, D. Dershaw, E. Chan, J. Nisselbaum, N. Alcock, P. Hollander, A. Yagoda, Cancer Treat. Rep., 1987, 71, 887.
• [23] A.M. Senderowicz, R. Reid, D. Headlee, T. Abornathy, J. Horti, R.M. Lush, E. Reed, W.D. Figg, E.A. Sausville, Urol. Int., 1999, 63, 120.
• [24] J.H. Malfetano, J.A. Blessing, M.D. Adelson, Am. J. Clin. Oncol., 1991, 14, 349.
• [25] J.H. Malfetano, J.A. Blessing, H.D. Homesley, P. Hanjani, Invest. New Drugs, 1991, 9, 109.
• [26] J.H. Malfetano, J.A. Blessing, H.D. Homesley, Am J. Clin. Oncol., 1995, 18, 495.
• [27] M.K. Samson, R.J. Fraile, L.H. Baker, R. O.Bryan, Cancer Clin. Trials, 1980, 3, 131.
• [28] P. Collery, B. Keppler, C. Madoulet, B. Desoize, Crit. Rev. Oncol. Hematol., 2002, 42, 283.
• [29] R. Niesvizky, C.G. Choy, D. Siegel, L. Lyons, J. Michaeli, Leukemia Lymphoma, 2002, 43, 603.
• [30] G. Apseloff, Am. J. Ther., 1999, 6, 327.
• [31] L.J. Anghileri, Arzneim.-Forsch. (Drug Res.), 1975, 25, 793.
• [32] L.J. Anghileri, M. Heidbreder, Oncology, 1977, 34, 74.
• [33] W.R. Harris, V.L. Pecoraro, Biochemistry, 1983, 2, 292.
• [34] W.R. Harris, L. Messori, Coord. Chem. Rev., 2002, 228, 237.
• [35] G. Kubal, A.B. Mason, S.U. Patel, P.J. Sadler, R.C. Woodworth, Biochemistry 1993, 32, 3387.
• [36] E.J. Beatty, M.C. Cox, T.A. Frenkiel, B.M. Tam, A.B. Mason, R.T.A. MacGillivray, P.J. Sadler, R.C. Woodworth, Biochemistry, 1996, 35, 7635.
• [37] H. Sun, M.C. Cox, H. Li, A.B. Mason, R.C. Woodworth, P.J. Sadler, FEBS Lett., 1998, 422, 315.
• [38] J. Clausen, C.J. Edeling, J. Fogh, Cancer Res., 1974, 34, 1931.
• [39] R.S. Vallabhajosula, J.F. Harwig, J.K. Siemens, W. Wolf, J. Nucl. Med., 1980, 21, 650.
• [40] G.R. Lee, [w:] Wintrobe.s Clinical Hematology (G.R. Lee, J. Foerster, J. Luksus, F. Paraskevas, J.P. Greer, G.M. Rodgers, eds), 10th ed., vol. 1, Williams & Wilkins, Baltimore, 1998, pp. 908.
• [41] H. Sun, H. Li, P.J. Sadler, Chem, Rev., 1999, 99, 2817.
• [42] S.R. Vallabhajosula, J.F. Harwig, W. Wolf, Int. J. Nucl. Med. Biol., 1981, 8, 363.
• [43] S.R. Vallabhajosula, J.F. Harwig, W. Wolf, Eur. J. Nucl. Med., 1982, 7, 462.
• [44] R.E. Weiner, G.J. Schreiber, P.B. Hoffer, T. Shannon, Int. J. Nucl. Med. Biol., 1981, 8, 371.
• [45] T. Higashi, M. Kobayashi, H. Wakao, Y. Jinbu, Eur. J. Nucl. Med., 1989, 15, 152.
• [46] R.G. Sephton, A.W. Harris, J. Natl. Cancer Inst., 1975, 54, 1263.
• [47] R.G. Sephton, A.W. Harris, Int. J. Nucl. Med. Biol., 1981, 8, 333.
• [48] S.M. Larson, Semin. Nucl. Med., 1978, 8, 193.
• [49] S.M. Larson, J.S. Rasey, D.R. Allen, N.J. Nelson, J. Nucl. Med., 1979, 20, 837.
• [50] U.K. Terner, H.Wong, A.A. Noujaim, B.C. Lentle, J.R. Hill, Int. J. Nucl. Med. Biol., 1979, 6, 23.
• [51] F. Planas-Bohne, D.M. Taylor, J.R. Duffield, Cell Biochem. Funct., 1985, 3, 217.
• [52] E. Aulbert, W. Disselhoff, H. Sorje, E. Schulz, D. Gericke, Eur. J. Cancer, 1980, 16, 1217.
• [53] P. Bichel, H.H. Hansen, Br. J Radiol. 1972, 45, 182.
• [54] T. Higashi, H. Wakao, M. Yamaguchi, K. Suga, Eur. J. Nucl. Med., 1981, 14, 155.
• [55] E.A. Van Leeuwen-Stok, A.R. Jonkhoff, A.W.J. Vissen-Platier, A.M. Drager, G.J.J. Teule, P.C. Huijgens, G.J. Schuurhuis, Leukemia Lymphoma, 1981, 31, 533.
• [56] E.A. Van Leeuwen-Stok, G.J. Schuurhuis, A.M. Drager, A.W.J. Visser-Platier, G.J.J. Teule, P.C. Huijgens, Br. J. Cancer, 1996, 74, 619.
• [57] E.A. Van Leeuwen-Stok, A.M. Drager, G.J. Schuurhuis, A.W.J. Visser-Platier, G.J.J. Teule, P.C. Huijgens, Int. J. Radiat. Biol., 1993, 64, 794.
• [58] W. Feremans,W. Bujan, P. Neve, J.P. Delville, L. Schandene, Am. J. Hematol, 1991, 36, 215.
• [59] A. Gallamini, A. Biggi, A. Fruttero, F. Pugno, G. Cavallero, M. Pregno, M. Grasso, C. Farinelli, A. Leone, E. Gallo, Eur. J Nucl. Med, 1997, 24, 1499.
• [60] F. Nejmeddine, M. Raphael, A. Martin, G. Le Roux, J.L. Moretti, N. Caillat-Vigneron, J. Nucl. Med., 1999, 40, 40.
• [61] Y. Tsuchija, A. Nakao, T. Komatsu, M. Yamamoto, K. Shimokata, Chest, 1992, 102, 530.
• [62] R.G. Sephton, G.S. Hodgson, S. De Abrew, A.W. Harris, J. Nucl. Med., 1978, 19, 930.
• [63] K.J. Kogan, P.K. Ng, C.J. Turner, R.P. Schmidt, U.K. Terner, J.R. Scott, B.C. Lentle, A.A. Noujaim, Int J. Nucl. Med. Biol, 1981, 8, 271.
• [64] R.E. Weiner, Nucl. Med. Biol., 1996, 23, 745.
• [65] G.E. Jackson, M.J. Byrne, J. Nucl. Med. 1996, 37, 379.
• [66] C.R. Chitambar, Z. Zivkovic, Cancer Res., 1987, 47, 3929.
• [67] M.H. Sohn, B.J. Jones, J.H. Whiting Jr., F.L. Datz, R.E. Lynch, K.A. Morton, J. Nucl. Med., 1993, 34, 2135.
• [68] C.R. Chitambar, D. Sax, Blood, 1992, 80, 505.
• [69] C.A. Luttropp, C. Vu, K.A. Morton, J. Nucl. Med., 1999, 40, 159.
• [70] P.T. Lieu, M. Heiskala, P.A. Peterson, Y. Yang, Mol. Asp. Med., 2001, 22, 1.
• [71] S.M. Chan, P.B. Hoffer, N. Maric, P. Duray, J. Nucl. Med., 1987, 28, 1303.
• [72] C.R. Chitambar, Z. Zivkovic-Gilgenbach, Cancer Res., 1990, 50, 1484.
• [73] R.E. Weiner, G.J. Schreiber, P.B. Hoffer, J. Nucl. Med., 1983, 24, 608.
• [74] R.E. Weiner, J Nucl. Med., 1989, 30, 70.
• [75] F.N. Hegge, D.J. Mahler, S.M. Larson, J. Nucl. Med., 1977, 18, 937.
• [76] M.D. Garrick, K.G. Dolan, C. Horbinski, A.J. Ghio, D. Higgins, M. Porubcin, E.G. Moore, L.N. Hainsworth, J.N. Umbreit, M.E. Conrad, L. Feng, A. Lis, J.A. Roth, S. Singleton, L.M. Garrick, BioMetals, 2003, 16, 41.
• [77] D.C. Swartzendruber, B. Nelson, R.L. Hayes, J. Natl. Cancer Inst., 1971, 46, 941.
• [78] D.H. Brown, D.C. Swartzendruber, J.E. Carlton, B.L. Byrd, R.L. Hayes, Cancer Res., 1973, 33, 2063.
• [79] E. Aulbert, A. Gebhardt, E. Schulz, U. Haubold, Nueklearmedizin, 1976, 15, 185.
• [80] O.L. Manfredi, L.R. Weis, NY State. J. Med., 1978, 78, 884.
• [81] P.A.G. Hammersley, D.M. Taylor, S. Cronshaw, Eur. J. Nucl. Med., 1980, 5, 411.
• [82] R.L. Hayes, Int. J. Nucl. Med. Biol., 1983, 10, 257.
• [83] T. Suzuki, M. Abiko, H. Kohno, Y. Ohkubo, A. Kubodera, Eur. J. Nucl. Med., 1986, 12, 47.
• [84] D.H. Brown, B.L. Byrd, J.E. Carlton, D.C. Swartzendruber, R.L. Hayes, Cancer Res., 1976, 36, 956.
• [85] K. Samezima, H. Orii, Eur J Nucl. Med., 1980, 5, 281.
• [86] J.P. Berry, F. Escaig, M.F. Poupon, P. Galle, Int. J. Nucl. Med. Biol., 1983, 10, 199.
• [87] J.P. Berry, M.F. Poupon, S. Galle, F. Escaig, Biol. Cell, 1984, 51, 43.
• [88] D.M. Taylor, Radiat. Prot. Dosim. 2000, 92, 229.
• [89] A.E. Van Leeuwen-Stok, G.J. Schuurhuis, A.M. Drager, A.W.J. Visser-Platier, E.B. Van Dieren, G.J.J. Teule, P.C. Huijgens, Int.J.Radiat.Oncol.Biol.Phys., 1996, 35, 507.
• [90] B.G. Mills, L.S. Masuoka, C.C. Graham Jr., F.R. Singer, A.D. Waxman, J. Nucl. Med., 29,1998, 1083.
• [91] J.R. Rasey, N.J. Nelson, S.M. Larson, Int.J.Nucl.Med.Biol., 1981, 8, 303.
• [92] J.R. Rasey, N.J. Nelson, S.M. Larson, Eur. J. Cancer. Clin. Oncol., 1982, 18, 661.
• [93] C.R. Chitambar, P.A. Seligman, J. Clin. Invest, 1986, 78, 1538.
• [94] J. Kovar, P. Seligman, E.W. Gelfand, Cancer Res.,1990, 50, 5727.
• [95] P.A. Seligman, R.B. Schleicher, G. Siriwardana, J. Domenico, E.W. Gelfand, Blood,1993, 82, 1608.
• [96] P.H. Schlezinger, S.L. Teitelbaum, H.C. Blair, J. Bone Miner. Res., 1991, 6 (suppl.1), S127.
• [97] H.C. Blair, S.L. Teitelbaum, H.L. Tan, C.M. Koziol, P.H. Schlezinger, Am. J. Physiol., 1991, 260, C1315.
• [98] N. Nelson,W.R. Harvey, Physiol. Rev, 1999, 79, 361.
• [99] C.R. Chitambar, Z. Zivkovic, Blood, 1987, 69, 144.
• [100] C.R. Chitambar, A. Craig, R.C. Ash, Exp. Hematol., 1989, 17, 418.
• [101] P.A. Seligman, P.L. Moran, R.B. Schleicher, E.D. Crawford, Am. J. Hematol., 1992, 41, 232.
• [102] C.R. Chitambar,W.G. Matthaeus,W.E. Antholine, K. Graff,W.J. O.Brien, Blood, 1988, 72, 1930.
• [103] C.R. Chitambar, J. Narasimhan, J. Guy, D.S. Sem, W.J. O'Brien, Cancer Res., 1991, 51, 6199.
• [104] C.R. Chitambar, J. Narasimhan, Pathobiology, 1991, 59, 3.
• [105] J. Narasimhan, W.E. Antholine, C.R. Chitambar, Biochem. Pharmacol., 1992, 44, 2403.
• [106] D.W. Hedley, E.H. Tripp, P. Slowiaczek, G.J. Mann, Cancer Res., 1988, 48, 3014.
• [107] M.A. Jakupec, B.K. Keppler, Medicinal Chemistry, 2004, 4, 1575.
• [108] T. Szekeres, M. Fritzer-Szekeres, H.L. Elford, Crit. Rev. Clin. Lab. Sci., 1997, 34, 503.
• [109] E.M. Perchellet, J.B. Ladesich, P. Collery, J.P. Perchellet, Anti-Cancer Drugs, 1999, 10, 477.
• [110] L. El-Mahdaoi, H.A. Tajmir-Riahi, J. Biomol. Struct. Dyn., 1995, 13, 69.
• [111] M. Manfait, P. Collery, Magnesium-Bull., 1984, 6, 153.
• [112] R. Ahmad, M. Naoui, J.F. Neault, S. Diamantoglou, H.A. Tajmir-Riahi, J. Biomol. Struct. Dyn., 1996, 13, 795.
• [113] M.M. Berggren, J.B. Burns, R.T. Abraham, G. Powis, Cancer Res., 1993, 53, 1862.
• [114] T.P. Waalkes, K. Sanders, R.G. Smith, R.H. Adamson, Cancer Res., 1974, 34, 385.
• [115] L.J. Anghileri, J. Robert, Magnesium-Bull., 1982, 4, 197.
• [116] C.R. Chitambar, E.J. Massey, P.A. Seligman, J. Clin. Invest., 1983, 72, 1314.
• [117] Y. Carpentier, F. Liataud-Roger, P. Collery, M. Loirette, B. Desoize, P. Coninx, [w:] Metal Ions in Biology and Medicine, (P. Collery, L.A. Poirier, M. Manfait, J.C. Etienne, eds), Libbey Eurotext, Paris, 1990, pp. 406.
• [118] R.U. Haq, J.P. Wereley, C.R. Chitambar, Exp. Hematol., 1995, 23, 428.
• [119] X.P. Jiang, F. Wang, D.C. Yang, R.L. Elliot, J.F. Head, Anticancer Res., 2002, 22, 2685.
• [120] J.H. Lundberg, C.R. Chitambar, Cancer Res., 1990, 50, 6466.
• [121] M.S. Myette, H.L. Elford, C.R. Chitambar, Cancer Lett, 1998, 129, 199.
• [122] Y. Hata, A. Sandler, P.J. Loehrer, G.W. Sledge Jr., G. Weber, Oncol. Res.,1994, 6,19.
• [123] P. Collery, F. Lechenault, E. Juvin, L. Khassanova, G. Vernet, A. Cazabat, A. Lebargy, [w:] Metal Ions in Biology and Medicine, vol.5 (P. Collery, P. Bratter, V. Negretti de Bratter, L. Khassanova, J.C. Etienne, eds), Libbey Eurotext, Paris, 1998, pp. 588.
• [124] R.C. Chitambar, J.P. Wereley, R. Ul-Haq, Cancer Res., 1994, 54, 3224.
• [125] C.R. Chitambar, S.A. Zahir, P.S. Ritch, T. Anderson, Am. J. Clin. Oncol.,1997, 20, 173.
• [126] L.H. Einhorn, B.J. Roth, R. Ansari, R. Dreicer, R. Gonin, P.J. Loehrer, J. Clin. Oncol., 1994, 12, 2271.
• [127] R. Dreicer, K.J. Propert, B.J. Roth, L.H. Einhorn, P.J. Loehrer, Cancer,1997, 79, 110.
• [128] R. Dreicer, T.A. Lallas, J.K. Joyce, B. Anderson, J.I. Sorosky, R.E. Buller, Am. J. Clin. Oncol., 1998, 21, 287.
• [129] F Wang, X Jiang, D.C. Yang, R.L. Elliot, J.F. Head, Anticancer Res., 2000, 20,799.
• [130] M.A. Jakupec, B.K. Keppler, Gallium and other main group metal compounds as antitumor agents, [w:] A. Siegel, H. Siegel (eds), Metal complexes in tumor diagnosis and as anticancer agents, New York, vol. 42, pp. 425.
• [131] L.R. Bernstein, T. Tanger, C Godfrey, B. Noll, Metal-Based Drugs, 2000, 7, 33.
• [132] P. Collery, J.L. Domingo, B.K. Keppler, Anticancer Res., 1996, 16, 687.
• [133] M. Thiel, T. Schilling, D.C. Gey, R. Ziegler, P. Collery, B.K. Keppler, Contrib. Oncol., 1999, 54, 439.
• [134] D. Gey, T. Schilling, B.K. Keppler, M. Thiel, H. Schmidt-Gayk, F. Raue, R. Ziegler, Exp. Clin. Endocrinol. Diabetes 1997, 105, Supl 1.
• [135] B.Winter, T. Schilling, D.C. Gey, B.K. Keppler, R. Ziegler, Exp. Clin. Endocrinol. Diabetes, 1998, 106, Supl 1, 83.
• [136] B. Desoize, B.K. Keppler, M.G. Akeli, J.C. Etienne, P Collery, Tris(8-quinolinato)Ga(III) is active against unicellular and multicellular resistance, [w:] J.A. Centeno, P. Collery, G. Vernet, R.B. Finkelman, H. Gibb, J.C. Etienne (eds) Metal Ions in Biology and Medicine 2000, 6: (Libbey Eurotext, Paris), pp. 573.
• [137] M.A. Jakupec, P. Collery, B.K. Keppler, Wells. Proc. Am. Ass. Cancer Res. 2001, 42, 425.
• [138] C.R. Chitambar, P. Boon, J.P. Wereley, Clin. Cancer Res.. 1996, 2, 1009.
• [139] G.M. Knorr, C.R. Chitambar, Anticancer Res., 1998, 18, 1733.
• [140] K.C. Agrawal, A.C. Sartorelli, Prog. Med. Chem., 1978, 15, 321.
• [141] R.W. Sidwell, J.H. Huffman, T.W. Scafer, C. Shipman, Chemotherapy, 1990, 36, 58.
• [142] C Shipman Jr, S.H. Smith, J.C. Drach, D.L. Klayman, Antiviral Res., 1986, 6, 197.
• [143] L. Thelander, A. Graslund, J. Biol. Chem., 1983, 258, 4063.
• [144] E.C. Moore, A.C. Sartorelli, Pharmacol. Ther., 1984, 24, 439.
• [145] J. Easmon, G. Purstinger, G. Heinisch, T. Roth, H.H. Fiebig, W. Holzer, W. Jager, M. Jenny, J. Hofmann, J. Med. Chem., 2001, 44, 2164.
• [146] M.C. Miller III, C.N. Stineman, J.R. Vance, D.X.West, I.H. Hall, Anticancer Res., 1998, 18, 4131.
• [147] M.C. Miller III, C.N. Stineman, J.R. Vance, D.X.West, I.H. Hall, Appl. Organomet. Chem., 1999, 13, 9.
• [148] F. Kratz, B. Nuber, J.Weiß, B.K. Keppler, Synth. React. Inorg. Met.-Org. Chem., 1991, 21, 1601.
• [149] V.B. Arion, M.A. Jakupec, M. Galanski, P. Unfried, B.K. Keppler, J. Inorg. Biochem., 2002, 91, 298.
• [150] P. Collery, F. Lechenault, A. Cazabat, E. Juvin, L. Khassanova, A. Evangelou, B. Keppler, Anticancer Res., 2000, 20, 955
• [151] M Galanski, V.B. Arion, M.A. Jakupec, B.K. Keppler, Curr. Pharm. Design, 2003, 9(25), 2078.
• [152] C.R. Kowol, K. Berger, R. Eichinger, A. Roller, M.A. Jakupec, P.P. Schmidt, V.B. Arion, B.K. Keppler, J. Med. Chem., 2007, 50, 1254.
• [153] A. Dobrov, V.B. Arion, N. Kandler,W. Ginzinger, M.A. Jakupec, A. Rufińska, N. Graf von Keyserlingk, M. Galanski, C. Kowol, B.K. Keppler, Inorg. Chem., 2006, 45, 1945.
• [154] R. Shakya, F. Peng, J. Liu, M.J. Heeg, C.N. Verani, Inorg. Chem, 2006, 45, 6263.
• [155] K. Mohammadi, K.H. Thompson, B.O. Patrick, T. Storr, C. Martins, E. Polishchuk, V.G. Yuen, J.H. McNeill, C. Orvig, J. Inorg. Biochem., 2005, 99, 2217.
• [156] V. Sharma, A. Beatty, S.-P.Wey, J. Dahlheimer, C.M. Pica, C.L. Crankshaw, L. Bass, M.A. Green, M.J. Welch, D. Piwnica-Worms, Chemistry & Biology, 2000, 7, 335.